Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 773-781, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcovina, S. M.
Right arrow Articles by Hannon, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcovina, S. M.
Right arrow Articles by Hannon, W. H.

Clinical Chemistry, Vol 39, 773-781, Copyright © 1993 by American Association for Clinical Chemistry

International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material

SM Marcovina, JJ Albers, LO Henderson and WH Hannon
Department of Medicine, University of Washington, Seattle 98103.

In the third phase of the International Federation of Clinical Chemistry (IFCC) study for the standardization of apolipoprotein (apo) measurements, the preparation SP1-01, selected as the candidate international reference material for apo A-I, was investigated for its ability to transfer an accuracy-based value to the immunoassay calibrators and to produce comparability of the values for patients' samples. An apo A-I value of 1.50 g/L (SD 0.08 g/L) was assigned to SP1- 01 by a highly standardized RIA calibrated with purified apo A-I for which the mass value had been determined by amino acid analysis. According to a common detailed protocol, the participants transferred the mass value from SP1-01 to the calibrator of each method. To confirm that uniformity of calibration ensures comparability of the values over a wide range of apo A-I values, each laboratory analyzed 50 fresh- frozen samples from individual donors, using an approach similar to that adopted by the Cholesterol Reference Laboratory Network. The consensus mean value for each sample was in excellent agreement with the value assigned by the Northwest Lipid Research Laboratories, with the average absolute bias between assigned and consensus value being 0.01 g/L. The among-laboratory CV on each of the 50 samples ranged from 2.1% to 5.6% (mean 3.6%), demonstrating that comparable apo A-I results can be obtained by a variety of immunochemical methods through the use of certified reference material. Based on the results obtained in these studies, SP1-01 has been approved as Apolipoprotein A-I International Reference Material by the World Health Organization.


The following articles in journals at HighWire Press have cited this article:


Home page
 Eur J Heart FailHome page
I. Holme, A. H. Aastveit, N. Hammar, I. Jungner, and G. Walldius
Lipoprotein components and risk of congestive heart failure in 84 740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS)
Eur J Heart Fail, November 1, 2009; 11(11): 1036 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Parish, R. Peto, A. Palmer, R. Clarke, S. Lewington, A. Offer, G. Whitlock, S. Clark, L. Youngman, P. Sleight, et al.
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls
Eur. Heart J., September 1, 2009; 30(17): 2137 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
H. R. Superko
Advanced Lipoprotein Testing and Subfractionation Are Clinically Useful
Circulation, May 5, 2009; 119(17): 2383 - 2395.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. M. Baca and G. R. Warnick
Estimation of LDL-Associated Apolipoprotein B from Measurements of Triglycerides and Total Apolipoprotein B
Clin. Chem., May 1, 2008; 54(5): 907 - 910.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
D. C. Crawford, A. S. Nord, M. D. Badzioch, J. Ranchalis, L. A. McKinstry, M. Ahearn, C. Bertucci, C. Shephard, M. Wong, M. J. Rieder, et al.
A common VLDLR polymorphism interacts with APOE genotype in the prediction of carotid artery disease risk
J. Lipid Res., March 1, 2008; 49(3): 588 - 596.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
W. A. van der Steeg, S. M. Boekholdt, E. A. Stein, K. El-Harchaoui, E. S.G. Stroes, M. S. Sandhu, N. J. Wareham, J. W. Jukema, R. Luben, A. H. Zwinderman, et al.
Role of the Apolipoprotein B-Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case-Control Analysis in EPIC-Norfolk
Ann Intern Med, May 1, 2007; 146(9): 640 - 648.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
J. S. Saczynski, L. White, R. L. Peila, B. L. Rodriguez, and L. J. Launer
The Relation between Apolipoprotein A-I and Dementia: The Honolulu-Asia Aging Study
Am. J. Epidemiol., May 1, 2007; 165(9): 985 - 992.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
D.C. Chan and G.F. Watts
Apolipoproteins as markers and managers of coronary risk
QJM, May 1, 2006; 99(5): 277 - 287.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al.
The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status
J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Meisinger, H. Loewel, W. Mraz, and W. Koenig
Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
Eur. Heart J., February 1, 2005; 26(3): 271 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Rifai, G. R. Cooper, W. V. Brown, W. Friedewald, R. J. Havel, G. L. Myers, and G. R. Warnick
Clinical Chemistry Journal Has Contributed to Progress in Lipid and Lipoprotein Testing for Fifty Years
Clin. Chem., October 1, 2004; 50(10): 1861 - 1870.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Averina, O. Nilssen, T. Brenn, J. Brox, V. L. Arkhipovsky, and A. G. Kalinin
Factors behind the Increase in Cardiovascular Mortality in Russia: Apolipoprotein AI and B Distribution in the Arkhangelsk Study 2000
Clin. Chem., February 1, 2004; 50(2): 346 - 354.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
G. P. Jarvik, T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al.
Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease
Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1465 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
G. Luc, J.-M. Bard, J. Ferrieres, A. Evans, P. Amouyel, D. Arveiler, J.-C. Fruchart, P. Ducimetiere, and on behalf of the PRIME Study Group
Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study
Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1155 - 1161.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
S. S. Levinson
High Density- and Beta-Lipoprotein Screening for Risk of Coronary Artery Disease in the Context of New Findings on Reverse Cholesterol Transport
Ann. Clin. Lab. Sci., April 1, 2002; 32(2): 123 - 136.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall
Risk factors for coronary heart disease: implications of gender
Cardiovasc Res, February 15, 2002; 53(3): 538 - 549.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. Sakai, V. S. Kamanna, and M. L. Kashyap
Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol
Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1783 - 1789.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. M. Marcovina, J. J. Albers, A. M. Scanu, H. Kennedy, F. Giaculli, K. Berg, R. Couderc, F. Dati, N. Rifai, I. Sakurabayashi, et al.
Use of a Reference Material Proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to Evaluate Analytical Methods for the Determination of Plasma Lipoprotein(a)
Clin. Chem., December 1, 2000; 46(12): 1956 - 1967.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
G. P. Jarvik, L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong
Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype
Arterioscler Thromb Vasc Biol, November 1, 2000; 20(11): 2441 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
N. Emanuele, N. Azad, C. Abraira, W. Henderson, J. Colwell, S. Levin, F. Nuttall, J. Comstock, C. Sawin, C. Silbert, et al.
Effect of Intensive Glycemic Control on Fibrinogen, Lipids, and Lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus
Arch Intern Med, December 1, 1998; 158(22): 2485 - 2490.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. Jungner, S. M. Marcovina, G. Walldius, I. Holme, W. Kolar, and E. Steiner
Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization–International Federation of Clinical Chemistry First International Reference Materials
Clin. Chem., August 1, 1998; 44(8): 1641 - 1649.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. A. Espeland, S. M. Marcovina, V. Miller, P. D. Wood, C. Wasilauskas, R. Sherwin, H. Schrott, and T. L. Bush
Effect of Postmenopausal Hormone Therapy on Lipoprotein(a) Concentration
Circulation, March 17, 1998; 97(10): 979 - 986.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
H. Schrott, A. G. Fereshetian, R. H. Knopp, H. Bays, P. H. Jones, T. W. Littlejohn, R. McLain, and D. M. Black
A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 119 - 123.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
M. S. Graziani, L. Zanolla, G. Righetti, C. Marchetti, P. Mocarelli, and S. M. Marcovina
Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group
Clin. Chem., January 1, 1998; 44(1): 134 - 140.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. R. McNamara, E. T. Leary, F. Ceriotti, C. M. Boersma-Cobbaert, T. G. Cole, D. J. Hassemer, M. Nakamura, C. J. Packard, D. W. Seccombe, M. M. Kimberly, et al.
Point Status of lipid and lipoprotein standardization
Clin. Chem., August 1, 1997; 43(8): 1306 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. D. Sniderman
Counterpoint To (measure apo)B or not to (measure apo)B: a critique of modern medical decision-making
Clin. Chem., August 1, 1997; 43(8): 1310 - 1314.
[Abstract] [Full Text]

Home page
 BloodHome page
S. K. Parsons, S. X. Skapek, E. J. Neufeld, C. Kuhlman, M. L. Young, M. Donnelly, J. D. Brunzell, J. D. Otvos, S. E. Sallan, and N. Rifai
Asparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukemia
Blood, March 15, 1997; 89(6): 1886 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
W. Y. Craig, S. E. Poulin, G. E. Palomaki, L. M. Neveux, R. F. Ritchie, and T. B. Ledue
Oxidation-Related Analytes and Lipid and Lipoprotein Concentrations in Healthy Subjects
Arterioscler Thromb Vasc Biol, June 1, 1995; 15(6): 733 - 739.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. W. Nawrocki, S. R. Weiss, M. H. Davidson, D. L. Sprecher, S. L. Schwartz, P.-J. Lupien, P. H. Jones, H. E. Haber, and D. M. Black
Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
Arterioscler Thromb Vasc Biol, May 1, 1995; 15(5): 678 - 682.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.